HOME >> BIOLOGY >> NEWS
Rethinking anti-oxidants

A leading researcher at the University of New South Wales (UNSW) points out that there is little convincing evidence that dietary antioxidant supplements such as vitamin E prevent heart disease, despite claims to the contrary.

Instead there has been a surprise finding, which relates to a synthetic antioxidant, the drug Probucol, which is no longer prescribed in Australia.

"There has been a lot of hype which suggested that antioxidant vitamin supplements had a beneficial outcome for cardiovascular disease. There is no good scientific support for the notion that people who suffer from atherosclerosis, or who are at elevated risk of heart disease, gain benefit by supplements of vitamin E," said Professor Roland Stocker, from the Centre for Vascular Research at UNSW, who will present his research at the ISTH Congress in Sydney today.

Stocker reported, "Our research is now leading towards the development of a new drug, based on Probucol. Probucol was previously used to reduce so-called "bad" cholesterol for those with heart disease, but it also had side effects, such as reducing "good" cholesterol and possibly inducing an irregular heartbeat.

This new compound, which has a similar structure to probucol, is very effective in protecting against atherosclerosis (the principal cause of coronary heart disease) in animal models but doesn't have the same side effects"

He went onto say, "We have shown that this novel probucol-analog induces a pathway in the vessel wall which is both anti-oxidative and anti-inflammatory. The early signs are that it provides strong protection for blood vessel walls. We are now progressing these studies further with a pharmaceutical company."

"This compound potentially represents a new approach for treating people with or at risk of heart disease at the source of the problem in the vessel wall. Vitamin E is not depleted or deficient in people with heart disease. It is in my view, a nave ide
'"/>

Contact: Sarah Meachem
Sarah.Meachem@phimr.monash.edu.au
61-412-640-774
Research Australia
9-Aug-2005


Page: 1 2

Related biology news :

1. Rethinking new therapies for Crohns disease at U.Va.

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rethinking anti oxidants

(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... word for chili peppers. Information about archaeological remains of ... of the appearance of words for chili peppers in ... domesticated and highlight the value of multi-proxy data analysis. ... of nine papers presented in a special feature issue ... Sciences on plant and animal domestication edited by ...
(Date:4/17/2014)... West Orange, NJ. April 16, 2014. Kessler Foundation ... for $1.8 million from the Department of Defense ... PhD, is principal investigator for the randomized, double-blinded, ... to improve bone and muscle strength after spinal ... Human Performance & Engineering Research at Kessler Foundation. ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
Cached News: